New Wearable Enables Around-the-Clock Glucose and Ketone Monitoring for Diabetes

The FDA has authorized Abbott Diabetes Care’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 and older with diabetes, making it the first US wearable to continuously monitor ketones and the first system globally to track glucose and ketones together. The device measures both analytes under the skin every minute, streams readings to a smartphone, and can send alerts for rising ketone levels. Supported by six studies with over 600 participants, it identified elevated ketones before the onset of diabetic ketoacidosis (DKA), potentially enabling earlier intervention and sick-day management. Ketone readings should be interpreted with glucose data and symptoms. This breakthrough device is particularly relevant as roughly 40 million Americans have diabetes, and clinicians will need guidance on sick-day protocols and insulin adjustments. Reference data from the FDA and CDC are cited in the release.
- FDA Authorizes First Wearable Device to Continuously Monitor Glucose, Ketones Patient Care Online
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes Abbott MediaRoom
- FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients Reuters
- FDA approves first wearable device to monitor glucose, ketone levels upi.com
- FDA issues novel nods for diabetes monitor, migraine lenses pharmaphorum
Reading Insights
0
2
24 min
vs 26 min read
97%
5,006 → 141 words
Want the full story? Read the original article
Read on Patient Care Online